Shotlee LogoShotlee
Blog
Download on theApp Store
Become aBeta Tester
Skip to main content
Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed - Featured image
GLP-1 Medications

Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed

Retired NFL star Tom Brady has taken on the role of Chief Wellness Officer at eMed, a digital health company specializing in GLP-1 medications such as Wegovy and Zepbound. These popular weight-loss drugs offer game-changing results when paired with clinical guidance. Brady's move highlights the growing intersection of sports fame and evidence-based weight management.

Shotlee·January 18, 2026·Updated Jan 27, 2026·2 min read
Share:

Contents

  1. 01Tom Brady's Pivot to Business Leadership
  2. 02Entry into GLP-1 Medications
  3. 03Sports Team Ownership Stakes
  4. 04Fashion and Wellness Brands
  5. 05Broadcasting and Media Ventures
  6. 06Other Investments and Endorsements

Tom Brady's Pivot to Business Leadership

Tom Brady, one of the NFL's greatest quarterbacks with seven Super Bowl wins and five MVP awards, has channeled his competitive drive into business. After retiring, he invests in dozens of companies across sports, wellness, and more. His net worth stands at an estimated $530 million, per Forbes.

Entry into GLP-1 Medications

Brady recently became Chief Wellness Officer at eMed Population Health, a digital health firm specializing in GLP-1 medications. These drugs, including Wegovy (semaglutide) for weight loss and Zepbound (tirzepatide) for diabetes and obesity, have surged in popularity.

Brady emphasizes eMed's mission to improve population health through scalable GLP-1 care for workforces. "These are game-changing drugs if paired with clinical guidance," he stated. For users, tools like apps that track GLP-1 doses—such as Shotlee—support adherence and monitoring.

Sports Team Ownership Stakes

Brady maintains strong ties to sports with minority ownership in Las Vegas teams. He owns stakes in the NFL's Las Vegas Raiders (5%) and WNBA's Las Vegas Aces.

  • Raiders deal finalized in 2023; amount undisclosed.
  • Aces investment followed a 2022 game, impressed by women's basketball growth, per owner Mark Davis.

He also founded the Las Vegas Night Owls pickleball team in 2022, capitalizing on America's fastest-growing sport, according to a 2025 Sports & Fitness Industry study. In 2023, Brady acquired a 3.3% stake in English soccer club Birmingham City.

"I've got a lot to learn... but I do know a few things about winning," Brady told ESPN.

Fashion and Wellness Brands

Brady's sportswear brand, Brady Brand Clothing, launched in 2022 and merged with NOBULL in 2024, making him a major shareholder. Under NOBULL is TB12, his 2013 co-founded wellness brand offering plant-based protein powders and electrolyte supplements.

Track your medication journey

Join thousands using Shotlee to track GLP-1 medications.

📱 Get the Shotlee App

Track your GLP-1 medications, peptides, and health metrics on the go with our mobile app!

Download on theApp Store
Become aBeta Tester

This aligns with the $1.8 trillion U.S. wellness industry, where GLP-1 medications play a key role in weight management.

Broadcasting and Media Ventures

In 2022, Brady signed a 10-year, $375 million Fox Sports deal—the largest in sportscasting history. He un-retired briefly but now analyzes games with Kevin Burkhardt, under restrictions due to Raiders ownership.

His 199 Productions develops sports content, including Emmy-winning "Man in the Arena" and Netflix's "The Greatest Roast of All Time: Tom Brady."

Other Investments and Endorsements

Brady co-founded NFT platform Autograph in 2021, which pivoted post-market crash and merged with Future in 2025. He holds a 50% stake in sports card retailer CardVault by Tom Brady.

Endorsements include Hertz for electric and used cars, with Executive VP Jeff Adams praising his MVP status in the used car market.

Original source: The Independent

View original article →
#GLP-1 medications#Tom Brady GLP-1#Wegovy#Zepbound#weight loss drugs#chief wellness officer#eMed health#semaglutide#tirzepatide
  1. Home
  2. Blog
  3. Tom Brady's GLP-1 Role: Chief Wellness Officer at eMed

Related Articles

Novo's Woes Despite Ozempic's Explosive Growth
GLP-1 Medications

Novo's Woes Despite Ozempic's Explosive Growth

Novo Nordisk's Ozempic pioneered the GLP-1 revolution, tripling sales to 309 billion DKK in eight years. Yet shares have cratered 60% due to Eli Lilly's Mounjaro gains, trial disappointments, and looming generics. Discover the booming market's challenges and opportunities.

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations
GLP-1 Medications

Millennial Stars Admit to Ozempic & GLP-1 Use: Transformations

Midlife weight gain is hitting millennial stars hard, but many are turning to Ozempic and other GLP-1s for help. Celebrities including Amy Schumer, Golnesa 'GG' Gharachedaghi, and Serena Williams have openly admitted to using these medications, sharing their triumphs, side effects, and transformations. Discover their stories and the science behind these popular drugs.

Novo Nordisk Slashes Wegovy Prices 50%, Ozempic 35% in 2027
GLP-1 Medications

Novo Nordisk Slashes Wegovy Prices 50%, Ozempic 35% in 2027

Novo Nordisk is dramatically reducing prices for its blockbuster GLP-1 drugs, slashing Wegovy by 50% and Ozempic by 35% to $675 per month starting in January 2027. This move addresses calls for affordability from patients and payers facing high-deductible plans. Amid fierce competition from Eli Lilly's Mounjaro and Zepbound, these cuts could broaden access to these transformative medications.

Shotlee LogoShotlee

Your comprehensive health tracking companion. Track, analyze, and optimize your journey with advanced metrics and community support.

Product

  • Get Started

Resources

  • Health Blog
  • Support Center
  • System Status

Legal

  • Privacy Policy
  • Terms of Service
  • Community Guidelines
  • Refund Policy

© 2026 Shotlee. All rights reserved.

Made with ♥ for the community